India, Nov. 14 -- Novo Nordisk (NVO) announced positive primary results from the Phase 3 REDEFINE 9 trial evaluating CagriSema, an investigational treatment for adults with overweight or obesity. CagriSema combines the long-acting amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide in a fixed-dose formulation.
The REDEFINE 9 study is the first Phase 3 weight-management trial to assess CagriSema at doses below the maximum 2.4 mg/2.4 mg level used in the broader REDEFINE clinical program.
Results showed that patients treated with CagriSema 1.7 mg/1.7 mg achieved an estimated average weight loss of 20.7% after 68 weeks, while those receiving the 1.0 mg/1.0 mg dose achieved a 21.0% average weight reduction. In comparison,...